20051
ORBO™ Amberlite™ XAD-2チューブ
W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea
別名:
ORBO™ 609 Amberlite™ XAD®-2 (20/50) 400/200 mg
material
W,W,W separators
agency
NIOSH 2534,2537
product line
Amberlite™, ORBO™
composition
Bed A, 400 mg , Bed B, 200 mg
packaging
pkg of 50 ea
manufacturer/tradename
ORBO™ 609
technique(s)
active air sampling: suitable
O.D. × L
8 mm × 110 mm
matrix
XAD-2
particle size
20-50 mesh
application(s)
air monitoring
environmental
industrial hygiene
Quality Level
関連するカテゴリー
General description
ORBO™ 609 Amberlite™ XAD®-2 (20/50)、400/200 mg吸着剤チューブ（W、W、Wセパレーター、O.D. × L 8 mm × 110 mm）には、ガラス綿またはガラスフォームで分離された同じ選択性吸着剤が2床含まれ、ガスおよび蒸気のサンプリングに使用されます。このチューブの二重層すなわち2床構造により、サンプルが急増しても小型のバックアップ床に捕捉できます。
Legal Information
Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
20051:
jan
A Ørbo et al.
BJOG : an international journal of obstetrics and gynaecology, 123(9), 1512-1519 (2015-12-03)
To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena(®) ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response. A multicentre
A Orbo et al.
Gynecologic oncology, 95(1), 82-88 (2004-09-24)
The purpose of the current study was to characterize the role of PTEN in malignant transformation and to evaluate the significance of mutated PTEN exons as prognostic markers in the carcinogenesis of endometrial hyperplasia. A comparison of PTEN mutations as
A Orbo et al.
International journal of oncology, 5(3), 619-625 (1994-09-01)
About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as
H Stalsberg et al.
Virchows Archiv. A, Pathological anatomy and histopathology, 414(5), 415-422 (1989-01-01)
The autopsies of 12 victims from two snow avalanches in North-Norway are reported. Supportive evidence from non-autopsied and surviving victims is included. Consistent autopsy findings were prominent lung oedema, moderate cerebral oedema, extreme contraction of the left ventricle, petechiae in
Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）